DB:6LJ

Stock Analysis Report

Executive Summary

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6LJ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.0%

6LJ

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

39.6%

6LJ

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 6LJ exceeded the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 6LJ exceeded the German Market which returned 13.7% over the past year.


Shareholder returns

6LJIndustryMarket
7 Day7.0%-2.3%-0.2%
30 Day-7.5%-3.2%0.3%
90 Day18.3%6.3%3.7%
1 Year39.6%39.6%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?

5.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6LJ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6LJ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6LJ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6LJ is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6LJ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6LJ is overvalued based on its PB Ratio (6x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

42.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6LJ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6LJ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6LJ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6LJ's revenue (79.8% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 6LJ's revenue (79.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6LJ's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Matinas BioPharma Holdings performed over the past 5 years?

-13.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6LJ is currently unprofitable.

Growing Profit Margin: 6LJ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6LJ is unprofitable, and losses have increased over the past 5 years at a rate of -13.1% per year.

Accelerating Growth: Unable to compare 6LJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6LJ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6LJ has a negative Return on Equity (-40.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Matinas BioPharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 6LJ's short term assets ($34.3M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: 6LJ's short term assets ($34.3M) exceed its long term liabilities ($4.2M).


Debt to Equity History and Analysis

Debt Level: 6LJ is debt free.

Reducing Debt: 6LJ had no debt 5 years ago.


Balance Sheet

Inventory Level: 6LJ has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 6LJ's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6LJ has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6LJ has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -15% each year.


Next Steps

Dividend

What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6LJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6LJ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6LJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6LJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6LJ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jerry Jabbour (45yo)

1.9yrs

Tenure

US$1,254,727

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M ...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD1.25M) is above average for companies of similar size in the German market ($USD625.18K).

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder1.9yrsUS$1.25m0.21% $486.3k
Raphael Mannino
Senior VP & Chief Scientific Officer4.4yrsUS$294.64k0.73% $1.7m
Keith Kucinski
Chief Financial Officer1.1yrsno data0.048% $113.0k
Theresa Matkovits
Chief Development Officer1.3yrsno datano data
Frank Calamusa
Executive Director and Head of Manufacturing & Supply Chain1.3yrsno datano data
James Ferguson
Chief Medical Officer1yrsno datano data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 6LJ's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder1.9yrsUS$1.25m0.21% $486.3k
Patrick LePore
Vice Chairman of the Board1.4yrsUS$159.45k0.15% $358.6k
Herbert Conrad
Chairman of the Board6.6yrsUS$256.00k2.27% $5.3m
Adam Stern
Director6.6yrsUS$210.00k1.16% $2.7m
James Scibetta
Independent Director6.3yrsUS$235.00k0.32% $738.2k
David Perlin
Member of Scientific Advisory Board4.6yrsno datano data
Christie Ballantyne
Member of Scientific Advisory Board1.2yrsno datano data
Eric Ende
Independent Director2.8yrsUS$231.50k0.056% $130.6k
J. Craft
Member of Scientific Advisory Board0yrsno datano data
Peter Pappas
Member of Scientific Advisory Board0yrsno datano data

3.7yrs

Average Tenure

54.5yo

Average Age

Experienced Board: 6LJ's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 6LJ insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.5%.


Top Shareholders

Company Information

Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Matinas BioPharma Holdings, Inc.
  • Ticker: 6LJ
  • Exchange: DB
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$251.550m
  • Listing Market Cap: US$233.087m
  • Shares outstanding: 195.00m
  • Website: https://www.matinasbiopharma.com

Number of Employees


Location

  • Matinas BioPharma Holdings, Inc.
  • 1545 Route 206 South
  • Suite 302
  • Bedminster
  • New Jersey
  • 7921
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTNBAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2014
6LJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides. The company’s lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. In addition, it provides MAT2501, an orally administered cochleate formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with ViiV Healthcare for the treatment and care for people living with human immunodeficiency virus. The company was founded in 2013 and is based in Bedminster, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:19
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.